HIV-1 Tat is present in the serum of people living with HIV-1 despite viral suppression.

Autor:	Shmakova A; CNRS, UMR 9018, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94800 France; Koltzov Institute of Developmental Biology, Moscow, 119334 Russia., Tsimailo I; CNRS, UMR 9018, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94800 France., Kozhevnikova Y; CNRS, UMR 9018, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94800 France., Gérard L; Service d'Immunopathologie Clinique, Hôpital St Louis, APHP, Paris, 75012 France., Boutboul D; Service d'Immunopathologie Clinique, Hôpital St Louis, APHP, Paris, 75012 France., Oksenhendler E; Service d'Immunopathologie Clinique, Hôpital St Louis, APHP, Paris, 75012 France., Tuaillon E; Pathogenesis and Control of Chronic and Emerging Infections, Montpellier University, INSERM U1058, Montpellier University Hospital, Montpellier, France., Rivault A; Institut de Recherche en Infectiologie de Montpellier, Université de Montpellier, CNRS UMR 9004, Montpellier, France., Germini D; CNRS, UMR 9018, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94800 France., Vassetzky Y; CNRS, UMR 9018, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94800 France; Koltzov Institute of Developmental Biology, Moscow, 119334 Russia. Electronic address: yegor.vassetzky@cnrs.fr., Beaumelle B; Institut de Recherche en Infectiologie de Montpellier, Université de Montpellier, CNRS UMR 9004, Montpellier, France.
Jazyk:	angličtina
Zdroj:	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2024 May; Vol. 142, pp. 106994. Date of Electronic Publication: 2024 Mar 04.
DOI:	10.1016/j.ijid.2024.106994
Abstrakt:	Objectives: Despite successful human immunodeficiency virus (HIV) control with combination antiretroviral therapy (cART), individuals with HIV still face health risks, including cancers, cardiovascular and neurocognitive diseases. An HIV protein, Tat, is potentially involved in these HIV-related diseases. Previous studies demonstrated circulating Tat in the blood of untreated people with HIV. Here, we measured Tat levels in the serum of cART-treated people with HIV to examine the effect of cART on Tat production. Methods: Serum samples from 63 HIV-positive and 20 HIV-seronegative individuals were analyzed using an ELISA assay that detected Tat concentrations above 2.5 ng/mL. Results: Among HIV-positive individuals, the Tat level ranged from 0 to 14 ng/mL. 25.4% (16 out of 63) exceeded the 2.5 ng/mL cut-off, with a median HIV Tat level of 4.518 [3.329-8.120] ng/mL. No correlation was revealed between Tat levels and CD4+ T cell counts, serum HIV RNA, p24 antigen, or anti-Tat levels. Conclusions: Despite cART, circulating HIV Tat persists and may contribute to HIV-related diseases. This emphasizes the need for further research on the mechanisms of Tat action in non-infected cells where it can penetrate upon circulation in the blood. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu